Global Gene Therapy Partnering Terms and Agreements 2010 to … – Business Wire (press release)
Posted: August 25, 2017 at 2:44 pm
DUBLIN--(BUSINESS WIRE)--The "Global Gene Therapy Partnering Terms and Agreements 2010 to 2017" report has been added to Research and Markets' offering.
The Global Gene Therapy Partnering Terms and Agreements 2010-2017 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter gene therapy partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapy technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest gene therapy, oligonucletides including aptamers agreements announced in the healthcare sectors.
Global Gene Therapy Partnering Terms and Agreements includes:
In Global Gene Therapy Partnering Terms and Agreements, the available contracts are listed by:
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Gene therapy dealmaking
Chapter 3 - Leading Gene therapy deals
Chapter 4 - Most active Gene therapy dealmakers
Chapter 5 - Gene therapy contracts dealmaking directory
Chapter 6 - Gene therapy dealmaking by technology type
Chapter 7 - Partnering resource center
For more information about this report visit https://www.researchandmarkets.com/research/7kw9kp/global_gene
See the original post:
Global Gene Therapy Partnering Terms and Agreements 2010 to ... - Business Wire (press release)
- Worldwide Markets for Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing, Forecast to 2030 - Robust Pipeline of Therapy Candidates and... - December 2nd, 2019
- Pfizer and Novartis lead pharma spending spree on gene therapy - Gulf Today - December 2nd, 2019
- Korean biotech's shares soar for a 'best of ESMO' award it never received - Endpoints News - December 2nd, 2019
- Insider account of UCB's $2.1B deal to buy Ra Pharma spotlights a disciplined M&A strategy and $120M windfall for execs - Endpoints News - December 2nd, 2019
- Global Gene Therapy for Age-related Macular Degeneration Market 2019 Development Status RetroSense Therapeutics, REGENXBIO, AGTC - Mach Tribune - December 2nd, 2019
- Harvard, MIT, teaching hospitals, industry partners pool resources to create a central facility for developing regenerative therapies - India... - December 2nd, 2019
- French-Swedish research team improves safety of DMD gene therapy - European Biotechnology - November 28th, 2019
- Time to Try Again: Gene-Based Therapy for Neurodegeneration - Alzforum - November 28th, 2019
- Partnership aims to accelerate cell and gene therapy - Harvard Gazette - November 28th, 2019
- Experts Barry Byrne, Jerry Mendell Lead NORD Webinar on Gene Therapy - SMA News Today - November 28th, 2019
- Pfizer, Novartis lead $2 billion spending spree on gene therapy production - Reuters - November 28th, 2019
- Global Gene Therapy Research Report 2019: Market Analysis, Trends, and Forecasts to 2025 - PRNewswire - November 28th, 2019
- UMass Med School gene therapy shows promising early results in tackling Tay-Sachs - Worcester Telegram - November 28th, 2019
- Sheffield research receives 800k to develop new gene therapy to treat CVD - News-Medical.net - November 28th, 2019
- Pfizer and Novartis lead $2bn spending on gene therapy production - Manufacturing Global - November 28th, 2019
- Hoth Therapeutics and North Carolina State University Enter License Agreement for Gene Therapy | More News | News Channels - PipelineReview.com - November 28th, 2019
- Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool - P&T Community - November 28th, 2019
- 'Breakthrough' bladder cancer drug spinout gets $570M to back launch of a new gene therapy in the US - Endpoints News - November 28th, 2019
- FDA approves 5 new costly drugs well ahead of PDUFA dates - Endpoints News - November 28th, 2019
- Gene Therapy and Antisense Drugs Market Growing Massively by 2019-2026 Major Players GenVec Inc., Avigen Inc., Genome Therapeutics Corp., Tekmira... - November 28th, 2019
- Feds add fraud charges to the multitude of accusations made against former MiMedx execs - Endpoints News - November 28th, 2019
- Cell and Gene Therapy Consumables Market Size, CAGR, Trends 2019: Industry Growth, Demand, Share, Analysis till 2027 - World Industry Reports - November 28th, 2019
- How AI is Changing the Way We Treat Diseases and Disabilities - Forbes - November 28th, 2019
- Intermountain to open new center for pediatric precision medicine - Healthcare IT News - November 28th, 2019
- Pfizer, Novartis lead pharma spending spree on gene therapy production - Reuters - November 28th, 2019
- Gene Therapy Market Expected to Grow with a CAGR of 16.92% During the Forecast Period, 2019-2024 - ResearchAndMarkets.com - Business Wire - November 28th, 2019
- Vertex plans major Boston expansion to support gene, cell therapy ambitions - FiercePharma - November 28th, 2019
- Hoth Therapeutics and North Carolina State University Enter License Agreement for Gene Therapy - P&T Community - November 28th, 2019
- Blackstone to invest $400 million in gene therapy venture with Ferring - Reuters - November 28th, 2019
- CODA Biotherapeutics Deepens Gene Therapy Expertise with Industry Veteran, Annahita Keravala, Ph.D., and Key Promotions - PRNewswire - November 28th, 2019
- New partnership aims to explore, cultivate innovations in cell and gene therapy - News-Medical.net - November 28th, 2019
- BIDMC joins local universities, teaching hospitals and industry partners in creating new central facility for regenerative therapies - Newswise - November 28th, 2019
- 6 Things About Biopharma to Be Thankful For - BioSpace - November 28th, 2019
- For Hemophilia A, BioMarin Seeks Approval of Its Gene Therapy in Europe - Hemophilia News Today - November 28th, 2019
- Mass General team presents mouse data to back the case for using reformulated asthma drug to treat ALS - Endpoints News - November 28th, 2019
- There's one endpoint that the booming biopharma industry has failed at miserably: financial toxicity - Endpoints News - November 28th, 2019
- Veloxis wins $1.3B buyout, and the new owner plans to follow up with new deals - Endpoints News - November 28th, 2019
- Another cancer vaccine play out of Geneva shoots for 'hard endpoint' in PhII head and neck cancer test - Endpoints News - November 28th, 2019
- Global Cancer Gene Therapy Market Report with Study of North America, Europe and Asia-Pacific, South America, Middle East and Africa Regions -... - November 28th, 2019
- Make that 2 new sickle cell disease blockbuster hopefuls OK'd by the FDA in just a few days - Endpoints News - November 28th, 2019
- How will Gene Therapy continue to evolve in the next 10 years? - Montana Ledger - November 28th, 2019
- Global Gene Therapy for Age-related Macular Degeneration Market Forecast (2019-2024) Report: By Regions, Type and Application with Sales and Revenue... - November 28th, 2019
- Axovant Gene Therapies Ltd (NASDAQ:AXGT) Expected to Post Earnings of -$0.63 Per Share - Mitchell Messenger - November 24th, 2019
- $6 Million Expansion For Gene Therapy Facility Completed At Alachua's Progress Park - WUFT - November 23rd, 2019
- Worldwide Cell & Gene Therapy Market Insights Study, 2019-2024 - Market Set to Surpass a CAGR of 24%, Driven by Favorable Regulatory Support & Special... - November 23rd, 2019
- Govt to fund gene therapy research on NCDs, rare diseases - CNBCTV18 - November 23rd, 2019
- Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder - Yahoo Finance - November 23rd, 2019
- Breakthrough Gene Therapy Clinical Trial is the World's First That Aims to Reverse 20 Years of Aging in Humans - PRNewswire - November 23rd, 2019
- Fujifilm to invest $120M in gene therapy, build center in Texas - BioPharma Dive - November 23rd, 2019
- 1.2m investment in Stevenage Bioscience Catalyst for world-class cell and gene therapy - Pharmafield - November 23rd, 2019
- Gene therapy to reverse age by 20 years: World's first trial - Specialty Medical Dialogues - November 23rd, 2019
- Gene Therapy Industry Analysis by Growth, Competitive Strategies and Forecast Research Report 2019-2025 - Markets Gazette 24 - November 23rd, 2019
- Trio of gene therapies seeks to reverse age-related diseases to make us 'healthy, youthful later in life' - Genetic Literacy Project - November 23rd, 2019
- Royal recognition for neuroscience research at the University of Sheffield - India Education Diary - November 23rd, 2019
- University of Sheffield receives Queen's Anniversary Prize for innovation in neuroscience - News-Medical.net - November 23rd, 2019
- Comprehensive Study Reveals How Sandhoff Disease Treatment Market is Trending | Intrabio, Axovant Gene Therapies Ltd - VaporBlash - November 23rd, 2019
- Edited Transcript of CLSD earnings conference call or presentation 6-Nov-19 9:30pm GMT - Yahoo Finance - November 23rd, 2019
- New Gene Therapy Aims At Reversing Signs Of Aging - TheHealthMania - November 23rd, 2019
- Vertex invests in gene therapy manufacturing - BioPharma-Reporter.com - November 11th, 2019
- Year in Review: Ophthalmology - MedPage Today - November 11th, 2019
- Hemophilia Patients, Caregivers Identify Factors in Switching Treatments - Hemophilia News Today - November 11th, 2019
- A New Treatment Method May Cure Patients of Genetic Hearing Loss - PharmiWeb.com - November 11th, 2019
- Global Bleeding Disorders Therapeutics Market 2020-2024 | Evolving Opportunities with Baxter International Inc. & Bayer AG | Technavio - Business... - November 11th, 2019
- GOVX: Third Quarter 2019 Results and Update - Zacks Small Cap Research - November 11th, 2019
- Gene Therapy Market Trends, Technology and Forecast | by Top Companies Novartis AG, MeiraGTx Limited, Rocket Pharmaceuticals, Lonza, Biogen, Gilead... - November 11th, 2019
- Modified Protein Enhances the Accuracy of CRISPR Gene Therapy - DocWire News - November 11th, 2019
- Scientists are using gene therapy to treat a heart disease in dogs. Could humans be next? - 10News - November 11th, 2019
- Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN4001, First Multigenic Investigational Therapeutic Candidate for... - November 11th, 2019
- Here Are the Early Results From the First US CRISPR Trial for Cancer - Philadelphia magazine - November 11th, 2019
- Gene Tech Company Claims to Have Found a Cure for HIV/AIDS - NewNowNext - November 11th, 2019
- 3 Cancer Treatment Stocks to Buy Right Now - The Motley Fool - November 11th, 2019
- How Gene Therapy Is Evolving to Tackle Complex... - Labiotech.eu - November 11th, 2019
- Sangamo Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at the American Society of Hematology Annual Meeting - Business... - November 11th, 2019
- Edited Transcript of VYGR earnings conference call or presentation 6-Nov-19 1:00pm GMT - Yahoo Finance - November 11th, 2019
- Latest Trending Report Cancer Gene Therapy Market Trends and Business Growth with Industry Share, Revenue , Key Highlights and Opportunity 2025 - The... - November 11th, 2019
- The woman who should have got Alzheimers by 50, but didnt - The Irish Times - November 11th, 2019
- Edited Transcript of SRPT earnings conference call or presentation 7-Nov-19 9:30pm GMT - Yahoo Finance - November 11th, 2019
- Orchard Therapeutics to Present New Registrational Data of Investigational Gene Therapies at the 61st American Society of Hematology Annual Meeting -... - November 11th, 2019
- Insightful Growth of Cancer Gene Therapy Market 2019- 2025| Research Methodologies Offers High Business Outlook growth - Daily Watch Reports - November 11th, 2019
- Her daughter may die by age 10, but this mom keeps fighting to cure her rare disease - GMA - November 11th, 2019